Back to Journals » Infection and Drug Resistance » Volume 3

Role of posaconazole in the treatment of oropharyngeal candidiasis

Authors Ianas V, Matthias KR, Klotz S

Published 28 June 2010 Volume 2010:3 Pages 45—51

DOI https://doi.org/10.2147/IDR.S10588

Review by Single-blind

Peer reviewer comments 3


Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz1

1Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USA

Abstract: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.
Keywords: posaconazole, azole, yeasts, filamentous fungi

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]